Acrux
- Short interest
- 0.21%
- +0.20 pp 30d
- as of 6 Dec 2024
- Reported shorts
- 611.8K
- Shares on issue
- 290.717M
Acrux (ACR) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $4.3Mvs $1.2M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- NPAT
- −$604.0Kvs −$5.9M (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.001vs −$0.017 (FY25)
- Yahoo Finance, as at 14 Oct 2026
- Rev YoY
- +261.2%FY
- EPS YoY
- n/aFY
Summary of FY26 Annual Report and Appendix 4E, 26 Aug 2026
Acrux Limited reported total revenue of $6.596 million for FY2026, up 46% from the prior year, while its net loss narrowed by 90% to $0.604 million. No dividend was declared or paid for the year. The company is focusing on developing Female Testosterone MDTS as a key growth opportunity.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- 100.0%
- Operating margin
- −57.8%
- Net margin
- −14.1%
- FCF margin
- 23.7%
- ROE
- −48.5%
- ROA
- −9.2%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $755.0K
- Net debt / EBITDA
- −3.0×
- Current ratio
- 1.4×
- Interest cover
- −8.8×
- Cash dividends paid / net profit
- n/a
- Market cap
- $6.3M
- P/E
- n/a
- P/B
- 4.3×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $4.3M | $1.2M | $5.1M | $8.4M |
| Gross profit | $4.3M | $1.2M | $1.1M | $7.9M |
| Operating income | −$2.5M | −$9.0M | −$8.6M | −$3.4M |
| EBITDA | $251.0K | −$5.2M | −$8.1M | −$2.8M |
| EBIT | −$187.0K | −$5.6M | −$8.6M | −$3.4M |
| Interest expense | $282.0K | $303.0K | n/a | n/a |
| Pretax income | −$469.0K | −$5.9M | −$5.6M | −$212.0K |
| Tax | $135.0K | $8.0K | $232.0K | $552.0K |
| NPAT | −$604.0K | −$5.9M | −$5.8M | −$764.0K |
| Net interest income | −$267.0K | −$263.0K | $134.0K | $122.0K |
| EPS basic | −$0.001 | −$0.017 | −$0.020 | −$0.003 |
| EPS diluted | −$0.001 | −$0.017 | −$0.020 | −$0.003 |
| Shares | 522.8M | 407.8M | 290.7M | 288.2M |
Financial reports
The company's own filings, newest first
- FY26 Annual Report and Appendix 4EAnnual Results26 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results25 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E and Full Year Statutory Accounts FY25Annual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
- Appendix 4D and December 2024 Half Year AccountsHalf Year Results25 Feb 2025via asx_announcements
Showing 10 of 77 reports